Dabigatran versus Warfarin in Patients with Atrial Fibrillation

J. Connolly, Stuart; D. Ezekowitz, Michael; Yusuf, Salim; W. Eikelboom, John; Oldgren, Jonas; Parekh, Amit; Pogue, Janice; Reilly, Paul; Themeles, Ellison; Varrone, Jeanne; Wang, Susan; Alings, Marco; Xavier, Denis; Zhu, Jun; Díaz, Rafael; S. Lewis, Basil; Darius, Harald; Diener, Hans‐Christoph; Joyner, Campbell; Wallentin, Lars

doi:10.1056/nejmoa0905561

Public

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Published in New England Journal of Medicine • Aug 30, 2009

Authors:

Stuart J. Connolly

Michael D. Ezekowitz

Salim Yusuf

Abstract

BACKGROUND: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. METHODS: In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillati...

Subject

Dabigatran

Medicine

Warfarin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!